Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Exclusion Criteria27

• Previous history of:
• esophageal adenocarcinoma/cancer
• esophageal squamous carcinoma
• endoscopic ablation for Barrett's esophagus
• esophageal squamous dysplasia
• Current treatment with oral anticoagulation including Warfarin, Coumadin
• History of cirrhosis
• History of esophageal/gastric varices
• History of Barrett's esophagus
• Prior endoscopy in the last 5 years
• Subjects with known BE.
• Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) alone will not be excluded.
• Patients with history of esophageal resection for esophageal carcinoma.
• For subjects with or without known evidence of BE (on history or review of medical records):
• Pregnant or lactating females.
• Patients who are unable to consent.
• Patients with current history of uninvestigated dysphagia (this does not apply to the brushings/biopsies only portion of the study).
• History of eosinophilic esophagitis, achalasia.
• Patients on oral anticoagulation including Coumadin, Warfarin (this does not apply to the brushings/biopsies only portion of the study).
• Patients on antiplatelet agents including Clopidogrel, unless discontinued for three to five days prior to the sponge procedure.
• Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for three to five days prior to the sponge procedure.
• Patients with history of known esophageal or gastric varices or cirrhosis.
• Patients with history of surgical esophageal resection for esophageal carcinoma.
• Patients with congenital or acquired bleeding diatheses.
• Patients with a history of esophageal squamous dysplasia.
• Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.
• Patient has received chemotherapy class drugs or radiation to treat mediastinal or esophageal cancer.